Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA).
OBJECTIVE
To evaluate if YKL-40 can provide prognostic information in patients with ischemic heart failure (HF) and identify patients who may benefit from statin therapy.


METHODS
The association between serum YKL-40 and predefined outcome was evaluated in 1344 HF patients assigned to rosuvastatin or placebo.


RESULTS
YKL-40 was not associated with outcome in adjusted analysis. In YKL-40 tertile 1, an effect on the primary outcome (HR 0.50, p = 0.006) and CV death (HR 0.54, p = 0.040) was seen by rosuvastatin in adjusted analysis.


CONCLUSIONS
A beneficial modification of outcome was observed with statin therapy in patients with low YKL-40 levels.
a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.|b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.|c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.
Fizza
F
Arain
a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.|c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.|d Faculty of Medicine , University of Oslo , Oslo , Norway.
Lars
L
Gullestad
b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.
Ståle
S
Nymo
a Department of Cardiology , Oslo University Hospital Rikshospitalet , Oslo , Norway.|c K.G. Jebsen Cardiac Research Centre and Center for Heart Failure Research , University of Oslo , Oslo , Norway.|d Faculty of Medicine , University of Oslo , Oslo , Norway.
John
J
Kjekshus
e Department of Cardiology , Hull York Medical School, University of Hull, Castle Hill Hospital , Kingston-upon-Hull, Glasgow , UK.
John G
JG
Cleland
b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.
Annika
A
Michelsen
f British Heart Foundation Glasgow Cardiovascular Research Centre , University of Glasgow , Glasgow , UK.
John J
JJ
McMurray
g Sahlgrenska University Hospital , Gøteborg , Sweden.
John
J
Wikstrand
b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.|d Faculty of Medicine , University of Oslo , Oslo , Norway.|g Sahlgrenska University Hospital , Gøteborg , Sweden.|h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway.|i Section of Clinical Immunology and Infectious Diseases , Oslo University Hospital Rikshospitalet Oslo , Norway.
Pål
P
Aukrust
b Research Institute of Internal Medicine , Oslo University Hospital Rikshospitalet , Oslo , Norway.|d Faculty of Medicine , University of Oslo , Oslo , Norway.|h K.G. Jebsen Inflammatory Research Center , University of Oslo , Oslo , Norway.|j K.G. Jebsen Thrombosis Research and Expertise Center , University of Tromsø , Tromsø , Norway.
Thor
T
Ueland
D000368:Aged; D000071451:Chitinase-3-Like Protein 1 / Q000097:blood*; D002908:Chronic Disease; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D000068718:Rosuvastatin Calcium / Q000627:therapeutic use*; D016896:Treatment Outcome
C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000068718:Rosuvastatin Calcium
Heart failure; YKL-40; mortality; risk prediction